Senior Experts from Nordic Bioscience, Biomarker Strategies and Pharma on Panel
WALTHAM, Mass., May 12 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that CEO Lewis H. Bender will moderate and co-present a panel discussion titled "Integrating Genetic Markers in Drug Development: How Personalized Medicine is Evolving Predictive Treatment" at the BIO International Convention, being held May 18-21, 2009 in Atlanta, GA. The panel discussion will be held Tuesday, May 19 from 8-9:30 a.m. in Room B304 of the Georgia World Congress Center (Building B).
Co-presenting alongside Interleukin Genetics will be Reid Leonard, Ph.D., Executive Director of Licensing and External Research, Merck Research Laboratories; Douglas Clark, M.D., Chief Scientific Officer, Biomarker Strategies; and Morten Karsdal, Ph.D., Vice President, Research and Development, Nordic Bioscience.
"Biomarkers can be effectively used to improve the success rate in drug development. Genetic biomarkers that can be used to screen and select for patients in clinical trials to improve likelihood of trial success and improve safety for patients can save costs and reduce the time needed to bring new compounds to market," said Mr. Bender. "We're pleased that the Biotechnology Industry Organization recognizes the importance of this topic by selecting this panel to present."
The panel will provide expert insights, respectively, on integration and commercialization issues for biomarkers in drug development and how simple genetic tests and other types of biomarkers are poised to help curb an increasing innovation gap especially with regard to complex diseases. Discussion will focus on:
|SOURCE Interleukin Genetics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved